Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check2 days agoChange DetectedThere are no additions or deletions listed for this study in the provided changes data, so the study record remains unchanged.SummaryDifference0.1%

- Check9 days agoChange DetectedAdded dates 2026-09-01, 2025-12-31, and 2026-08-28; removed 2026-08-26, 2026-03-05, and 2026-08-24 from the Study Record Dates, reflecting updates to the record’s milestone and revision history.SummaryDifference0.3%

- Check16 days agoChange DetectedThe study record now shows completion with updated primary completion and study completion dates, and a new page revision (v3.6.6), replacing the previous active, not recruiting status.SummaryDifference0.6%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedThe Study Record Dates section now shows Revision: v3.6.5, indicating a new revision of the page entry. No study details, enrollment information, or eligibility criteria appear to be altered.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, signaling a new version of the page. This indicates a maintenance update without altering the study information.SummaryDifference0.1%

- Check66 days agoChange DetectedThe study record includes metadata updates: a new last update date, revised estimated study completion dates, and removal of the old registry identifier, with other historical dates added. These changes update timeline and registry references but do not modify treatment, eligibility, or participating locations.SummaryDifference0.4%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.